What Ectosense does

Ectosense is a Belgium-based medtech company founded in 2015 that developed the NightOwl Home Sleep Test, a consumer-grade device enabling patients to diagnose obstructive sleep apnea without attending a clinic or sleep center. The product consists of the NightOwl Sensor hardware and a NightOwl Companion mobile application used by patients and healthcare providers, with the sensor transmitting data for clinical review. Ectosense operated as a small, sub-ten-person R&D and product company headquartered in Rotselaar, Belgium, with Ciaran McCourt serving as CEO and early backing from imec.istart (2015) and Saffelberg Investments (2018).

The company monetized the NightOwl device through one-time per-unit sales; following ResMed's April 2025 acquisition and subsequent relaunch, the product is positioned at approximately $140 per unit and distributed through ResMed's global healthcare provider channel across North America, Europe, Australia and New Zealand, and Asia. Ectosense's strategic target is the estimated 936 million people worldwide with undiagnosed sleep apnea, with explicit commercial emphasis on GLP-1 weight-loss drug patients, a cohort reported by ResMed to convert to CPAP therapy at an 11% higher rate than the general population.

Post-acquisition, Ectosense no longer operates as an independent entity; the NightOwl brand, technology, FDA-cleared IP, and product line have been integrated into ResMed's sleep and respiratory care portfolio, with regional patient and HCP support operations handling inbound inquiries under ResMed email domains. Independent revenue, headcount growth, and product pipeline metrics are no longer separately disclosed.

Name

Ectosense

Website

https://ectosense.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

1–10 employees

Short description

Ectosense is a Belgium-based medtech company that developed the NightOwl home sleep test device and companion app for at-home sleep apnea diagnosis. It was acquired by ResMed in 2025, after which the product was relaunched at approximately $140 per unit and distributed globally through ResMed's healthcare provider channel.

Ownership category

akta.pro rank

Product category

Sleep Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)

Keywords

• Home sleep testing
• Sleep apnea diagnosis
• Sleep medicine devices
• Respiratory diagnostics
• Medical technology

Headquarters

HQ city

Rotselaar

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Home Sleep Test Device Sales: Ectosense developed and sold the NightOwl home sleep testing device. The company was subsequently acquired by Resmed, who now commercializes the product at approximately $140 per unit.

Pricing tiers

Distribution channels2 records

Marketing channels2 records

Core offering

Ectosense developed and sold the NightOwl, a home sleep testing device for diagnosing sleep apnea. The product enables patients to conduct sleep apnea diagnosis without visiting a clinic or sleep center. Ectosense was acquired by ResMed, which relaunched the NightOwl device in April 2025 at approximately $140 per unit as part of its strategy to reduce diagnostic bottlenecks and address the estimated 936 million people worldwide with undiagnosed sleep apnea.

Product overview

Ectosense's primary product was NightOwl, a home sleep test device for diagnosing sleep apnea. The company was acquired by ResMed, which relaunched NightOwl in April 2025 as part of its diagnostic strategy. The offering consists of the NightOwl Sensor hardware and the companion NightOwl Companion app for patient and healthcare provider interaction.

Differentiator

Problem solved

Functional benefit

Products and services

• NightOwl Home Sleep Test A home sleep test device for diagnosing sleep apnea that enables patients to conduct diagnosis without visiting a clinic or sleep center. Acquired by ResMed through Ectosense and relaunched in April 2025. Designed for healthcare providers and patients as part of the sleep apnea diagnostic pathway.
• NightOwl Companion App Mobile application paired with the NightOwl Sensor for sleep testing. Available for patients and healthcare providers with regional support contacts across North America, Europe, Australia/New Zealand, and Asia.

Quantifiable outcome

• Resmed reports that GLP-1 weight loss drug users show 11% higher CPAP adoption rates and higher long-term mask purchasing compared to non-GLP-1 patients, indicating higher diagnosis-to-treatment conversion

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Regional players

• BMC Medical: China-based manufacturer of respiratory and sleep care devices including home sleep testing and CPAP products. Comparable regional player in the sleep diagnostic and therapy category with overlapping product set.

Broad incumbents

• Philips Respironics: Global incumbent in sleep apnea and respiratory care with both diagnostic (Alice PSG) and therapy (CPAP) portfolios. Comparable as a broad incumbent whose diagnostic offering overlaps with NightOwl's category.
• Fisher & Paykel Healthcare: Major respiratory care and sleep apnea therapy manufacturer with growing diagnostic-adjacent offerings. Relevant as a broad incumbent operating in the same downstream sleep apnea care pathway.

Emerging players

• Apple: Apple Watch has received FDA clearance for sleep apnea notifications, positioning the consumer wearable as an emerging low-friction screening alternative to dedicated home sleep tests like NightOwl.
• Withings: Maker of connected health devices including sleep tracking mats (Withings Sleep Analyzer) that screen for sleep apnea, representing a consumer-grade alternative to clinical home sleep tests like NightOwl.
• Oura: Oura Ring has introduced sleep apnea detection features, positioning it as an emerging consumer wearable competitor that could compete with dedicated home sleep testing devices for screening-stage demand.

Direct peers

• Itamar Medical: Acquired by ZOLL Medical/Itamar Medical, maker of the WatchPAT home sleep apnea test — a direct competitor to NightOwl in the at-home sleep diagnostic device category, with similar FDA-cleared disposable-sensor architecture.
• CleveMed: Provider of home sleep testing systems (SleepView, BioNomadix) for sleep apnea screening. Competes head-to-head with NightOwl in the prescription home sleep test market for healthcare providers.
• Nox Medical: Manufactures the Nox T3 and Nox A1 home sleep testing/PSG systems used by sleep specialists and research labs. Directly comparable as a home sleep diagnostic device vendor serving the same clinical pathway as NightOwl.

Others

• ResMed: Acquirer of Ectosense and now the commercial vehicle for NightOwl; while not a peer in the competitive sense, ResMed is the most relevant comparable for assessing scale, distribution, and downstream CPAP economics tied to NightOwl.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ectosense